Patient
SITE010-0152
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE010 (ESP) (Dr. Silva)
consented 2026-03-05
Adverse events
9
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 9
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-19 (study day 70); relationship: NOT RELATED
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-19 (study day 70); relationship: NOT RELATED
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-11-01 (study day 52); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-27 (study day 47); relationship: NOT RELATED
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-10-27 (study day 47); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-24 (study day 44); relationship: NOT RELATED
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-10-21 (study day 41); relationship: not assessed
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-10-08 (study day 28); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: UNKNOWN; onset 2022-09-22 (study day 12); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.